ClinicalTrials.gg
CompletedNCT03018691Updated Jul 23, 2020Results posted

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

A Phase 2 interventional study of OPA-15406 and Placebos in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 4 sites in Japan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2020-07-23.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
13th of 16
73 · median 177
Started
2017
the only one that year
Phase 2
4 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 4 in phase 2, and was the 6th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of atopic dermatitis based on the criteria of Hanifin and Rajka

Exclusion criteria

Exclusion Criteria:

  • Subjects who have an atopic dermatitis or contact dermatitis flare-up defined as a sudden intensification of atopic dermatitis.
  • Subjects who have an active viral skin infection.
  • Subjects with a current or history of .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    0.3% OPA-15406 Ointments

    Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.

    Drug: OPA-15406

  • Experimental
    1% OPA-15406 Ointments

    Subjects were treated with assigned 1% OPA-15406 ointment twice daily.

    Drug: OPA-15406

  • Placebo comparator
    Placebo Ointments

    Subjects were treated with assigned 0% OPA-15406 ointment twice daily.

    Drug: Placebos

Interventions

06

What researchers measure

Primary outcomes

  1. The Number of Subjects Experiencing AEs

    The number of subjects experiencing AEs will be calculated for each treatment group. Treatment-emergent adverse events (TEAEs) occurring after the start of IMP administration are summarized. The number of subjects with events, the number of events is obtained for all the TEAEs reported.

    Time frame: Week 0-4

Secondary outcomes

  1. Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4

    The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

    Time frame: Baseline and Week 4

  2. Change From Baseline in Eczema Area and Severity Index (EASI) Score

    The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

    Time frame: Baseline, Week 4

  3. Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score

    The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects aged 7 to 14 years old marked the point of pruritus intensity during the last 24 hours on a 0 to 100mm VAS, with 0 being no pruritis to 100 being very severe pruritis.For subjects aged 2 to 6 years, this would not be evaluated. The negative value showed the degree of improvement.

    Time frame: Baseline, Week 4

  4. Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score

    The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. The negative value showed the degree of improvement.

    Time frame: Baseline, Hour 156

  5. Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score

    The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

    Time frame: Baseline, Week 4

  6. Change From Baseline in Percentage Affected Body Surface Area

    The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA. The negative value showed the degree of improvement.

    Time frame: Baseline, Week 8, 16, 24

  7. Mean (SD) OPA-15406 Plasma Trough Concentrations at week1

    The plasma concentration of OPA-15406 was measured at Week 1. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.

    Time frame: Week 1

  8. Mean (SD) OPA-15406 Plasma Trough Concentrations at week4

    The plasma concentration of OPA-15406 was measured at Week 4. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.

    Time frame: week4

  9. Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week1

    The plasma concentration of OPA-15406 was measured at Week 1. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Each plasma concentration was normalized by dose.

    Time frame: week1

  10. Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week4

    The plasma concentration of OPA-15406 was measured at Week 4. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Each plasma concentration was normalized by dose.

    Time frame: week4

07

Results

Posted Jul 23, 2020

Participant flow

Participant flow — Overall Study
Milestone0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Started242524
Completed222417
Not completed217
Withdrew: Adverse event114
Withdrew: Lack of efficacy001
Withdrew: Withdrawal by subject001
Withdrew: Withdrawal by parent/guardian101

Outcome measures

PrimaryThe Number of Subjects Experiencing AEs

The number of subjects experiencing AEs will be calculated for each treatment group. Treatment-emergent adverse events (TEAEs) occurring after the start of IMP administration are summarized. The number of subjects with events, the number of events is obtained for all the TEAEs reported.

Time frame:
Week 0-4
Reported as:
Number · participants
The Number of Subjects Experiencing AEs
participants0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
The Number of Subjects Experiencing AEs111412
SecondaryResponder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4

The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week4. Incidence of success in IGA was defined as the rate of subjects whose IGA score was 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

Time frame:
Baseline and Week 4
Reported as:
Number · Percentage of participants
Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week4
Percentage of participants0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Responder Rate of Investigator's Global Assessment(IGA) of Disease Severity at Week437.50 (18.80 to 59.41)40.00 (21.13 to 61.33)8.33 (1.03 to 27.00)
SecondaryChange From Baseline in Eczema Area and Severity Index (EASI) Score

The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score
score on a scale0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Change From Baseline in Eczema Area and Severity Index (EASI) Score-5.33 ± 1.28-5.52 ± 1.260.56 ± 1.36
SecondaryChange From Baseline in Visual Analogue Scale(VAS) for Pruritus Score

The investigator or subinvestigator evaluated the level of pruritus based on VAS. The subjects aged 7 to 14 years old marked the point of pruritus intensity during the last 24 hours on a 0 to 100mm VAS, with 0 being no pruritis to 100 being very severe pruritis.For subjects aged 2 to 6 years, this would not be evaluated. The negative value showed the degree of improvement.

Time frame:
Baseline, Week 4
Reported as:
Mean · mm
Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score
mm0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Change From Baseline in Visual Analogue Scale(VAS) for Pruritus Score-18.00 ± 7.27-17.21 ± 7.298.19 ± 7.58
SecondaryChange From Baseline in Verbal Rating Scale(VRS) for Pruritus Score

The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. The negative value showed the degree of improvement.

Time frame:
Baseline, Hour 156
Reported as:
Mean · score on a scale
Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score
score on a scale0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Change From Baseline in Verbal Rating Scale(VRS) for Pruritus Score-0.83 ± 0.18-0.73 ± 0.190.30 ± 0.11
SecondaryChange From Baseline in Patient-Oriented Eczema Measure(POEM) Score

The investigator or sub investigator evaluated eczema according to the POEM. The subjects answered 7 questions about their eczema by 0-4 points per question. The POEMS's minimum and maximum scores are 0 and 28 scores respectively. The higher the POEM score is, the more severe the symptoms are, and a negative change from the baseline means improvement and a positive change means worsening. If it is difficult for subjects to answer the questions, their parents answered them instead. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.

Time frame:
Baseline, Week 4
Reported as:
Mean · score on a scale
Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score
score on a scale0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Change From Baseline in Patient-Oriented Eczema Measure(POEM) Score-4.33 ± 1.16-4.37 ± 1.142.26 ± 1.24
SecondaryChange From Baseline in Percentage Affected Body Surface Area

The investigator or subinvestigator drew the affected BSA (range of skin eruption at the time of examination) on the human body drawing to determine the affected areas (%) on the respective 4 body regions (face, neck, and head; upper limbs; trunk; and lower limbs). One palm of the subject corresponds to 1% BSA. The negative value showed the degree of improvement.

Time frame:
Baseline, Week 8, 16, 24
Reported as:
Mean · percentage of Affected Body Surface Area
Change From Baseline in Percentage Affected Body Surface Area
percentage of Affected Body Surface Area0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Change From Baseline in Percentage Affected Body Surface Area-6.06 ± 2.36-8.21 ± 2.321.78 ± 2.53
SecondaryMean (SD) OPA-15406 Plasma Trough Concentrations at week1

The plasma concentration of OPA-15406 was measured at Week 1. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.

Time frame:
Week 1
Reported as:
Mean · ng/mL
Mean (SD) OPA-15406 Plasma Trough Concentrations at week1
ng/mL0.3% OPA-154061% OPA-15406
Mean (SD) OPA-15406 Plasma Trough Concentrations at week10.842 ± 0.5772.90 ± 2.74
SecondaryMean (SD) OPA-15406 Plasma Trough Concentrations at week4

The plasma concentration of OPA-15406 was measured at Week 4. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.

Time frame:
week4
Reported as:
Mean · ng/mL
Mean (SD) OPA-15406 Plasma Trough Concentrations at week4
ng/mL0.3% OPA-154061% OPA-15406
Mean (SD) OPA-15406 Plasma Trough Concentrations at week40.946 ± 1.162.21 ± 1.81
SecondaryMean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week1

The plasma concentration of OPA-15406 was measured at Week 1. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Each plasma concentration was normalized by dose.

Time frame:
week1
Reported as:
Mean · ng/mL/mg
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week1
ng/mL/mg0.3% OPA-154061% OPA-15406
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week10.196 ± 0.2010.210 ± 0.174
SecondaryMean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week4

The plasma concentration of OPA-15406 was measured at Week 4. On the day of measurement, the subjects visited the trial site without morning Investigational Medicinal Product (IMP) administration.Each plasma concentration was normalized by dose.

Time frame:
week4
Reported as:
Mean · ng/mL/mg
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week4
ng/mL/mg0.3% OPA-154061% OPA-15406
Mean (SD) Normalized OPA-15406 Plasma Trough Concentrations by Dose Derived From %BSA at week40.150 ± 0.1110.166 ± 0.148

Adverse events

Collected over Treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.3% OPA-15406 Ointments0/24 (0%)0/24 (0%)6/24 (25%)
1% OPA-15406 Ointments0/25 (0%)0/25 (0%)8/25 (32%)
Placebo Ointments0/24 (0%)0/24 (0%)8/24 (33.3%)
Most frequent other events
Most frequent other events
Event0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo Ointments
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders1/246/252/24
Dermatitis atopicSkin and subcutaneous tissue disorders2/241/254/24
InfluenzaInfections and infestations2/241/250/24
Viral upper respiratory tract infectionInfections and infestations1/240/252/24
Blood alkaline phosphatase increasedInvestigations0/242/250/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo OintmentsTotal
<=18 years24252473
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(years)0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo OintmentsTotal
Mean8.5 ± 3.87.9 ± 3.58.5 ± 3.18.3 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo OintmentsTotal
Female610521
Male18151952
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo OintmentsTotal
Japanese Subjects24252473
Region of Enrollment
Region of Enrollment(Participants)0.3% OPA-15406 Ointments1% OPA-15406 OintmentsPlacebo OintmentsTotal
Japan24252473
08

Study locations

4 sites
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2017, 5 months.

Results were first posted in Jul 2020, 3 years 1 month after primary completion.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 5 months is below that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2017
First posted
Jan 12, 2017
StartActual
Jan 2017
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Results first posted
Jul 23, 2020
Last update
Jul 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03018691
Responsible party
Sponsor
First posted
Jan 12, 2017
Start date
Jan 2017
Primary completion
Jun 2017
Completion
Jun 2017
Results posted
Jul 23, 2020
Last update
Jul 23, 2020

Study contacts

Hiroaki Ono, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion